Eli Lilly tosses a marquee pain drug and hits the gas on Alzheimer’s — as Biogen’s suffering opens market to rivals
The furious chorus of critics that brought sales of Biogen’s ultra controversial Alzheimer’s drug aducanumab (sold as Aduhelm) to a near halt is opening …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
